TELA Bio, Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- TELA Bio, Inc. is a commercial-stage medical technology company specializing in the design, development, and marketing of innovative tissue reinforcement materials for soft tissue reconstruction. Its core product portfolio centers on OviTex Reinforced Tissue Matrix (RTM) products, including OviTex and OviTex PRS, which combine ovine rumen collagen and polymer fibers to provide biocomposite materials aimed at hernia repair, abdominal wall reconstruction, and plastic and reconstructive surgery. The OviTex platform also extends to specialized products such as OviTex for laparoscopic and robotic procedures and titanium-coated OviTex RTM designed for complex hernia repairs. These products seek to improve surgical outcomes by reinforcing tissue with materials that support natural tissue remodeling while minimizing long-term exposure to permanent synthetic materials. Founded in 2012 and headquartered in Malvern, Pennsylvania, TELA Bio operates primarily in the regenerative medicine and reconstructive surgery industries. The company serves a global market with a focus on hospitals and surgeons specializing in reconstructive procedures. It maintains a strong commercial presence supported by surgeon education programs, proprietary manufacturing processes for its OviTex RTM technology, and strategic distribution partnerships. The acquisition of Novus Scientific AB in 2023 expanded TELA Bio’s product offerings to include the TIGR Matrix product line, significantly broadening its tissue reconstruction solutions. This strategic move complemented its existing portfolio and assisted in driving market expansion. Recent major developments include robust financial performance with Q3 2025 revenue reaching $20.7 million, marking a 9% year-over-year increase, and the narrowing of operating losses. In 2025, TELA Bio revised its full-year revenue guidance to a 16% increase over 2024, with projections of $85 million to $88 million in total revenue reflecting continued growth. The company secured a $70 million credit facility from Perceptive Advisors to support growth initiatives. It also appointed Jeffrey Blizard as President to strengthen commercial leadership and launched OviTex Inguinal in Europe for robotic procedures. Additional inducement grants and a $13 million registered direct offering of common stock in late 2025 further highlight its strategic focus on financial stability and operational expansion. TELA Bio continues to emphasize innovation through ongoing research and development investments aimed at expanding its OviTex product line and enhancing clinical outcomes. Its proprietary biocomposite technology platform, combined with a targeted commercial strategy focusing on key surgical specialties such as hernia repair and reconstructive surgery, positions the company for growth in a market driven by increasing demand for advanced and minimally invasive surgical solutions. TELA Bio remains publicly traded on the NASDAQ under the ticker symbol TELA and operates with a governance structure supported by institutional and insider investors. The company maintains a commitment to providing cost-effective, on-demand soft tissue reconstruction solutions that improve patient outcomes and reduce healthcare costs across its geographic operations.
TELA Bio, Inc. (TELA) Q1 2026 Earnings Call Transcript
TELA Bio, Inc. (TELA) Reports Q1 Loss, Beats Revenue Estimates
TELA Bio Reports First Quarter 2026 Financial Results
TELA Bio Reports First Quarter 2026 Financial Results
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
TELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports Preliminary First Quarter 2026 Revenues
TELA Bio to Announce First Quarter 2026 Financial Results
TELA Bio Q4 Earnings Call Highlights
TELA Bio Analysts Cut Their Forecasts After Q4 Results
TELA Bio, Inc. (TELA) Q4 2025 Earnings Call Transcript
TELA Bio, Inc. (TELA) Reports Q4 Loss, Lags Revenue Estimates
TELA Bio Reports Fourth Quarter and Full Year 2025 Financial Results
TELA Bio, Inc. (NASDAQ:TELA) Given Average Rating of “Hold” by Brokerages
TELA Bio to Announce Fourth Quarter and Full Year 2025 Financial Results
Comparing TELA Bio (NASDAQ:TELA) & Quantum Genomics (OTCMKTS:QNNTF)
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
TELA Bio, Inc. (NASDAQ:TELA) Receives Consensus Recommendation of “Hold” from Analysts
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
TELA Bio to Participate in the Piper Sandler 37th Annual Healthcare Conference